Log in to your Inderes Free account to see all free content on this page.
Double Bond Pharmaceutical International
0.13 SEK
+8.94 %
Less than 1K followers
DBP B
Spotlight Stock Market
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+8.94 %
-8.24 %
+7.56 %
+7.56 %
+19.07 %
-62.16 %
-69.00 %
-89.95 %
-95.61 %
Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.
Read moreMarket cap
27.43M SEK
Turnover
73.84K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
DBP: Double Bond Pharmaceutical Announces Final Survival Data from Extensive Temodex Study: 5.6-Month Survival Advantage Confirmed
DBP: Double Bond Pharmaceutical Collaborates with Karolinska Institutet in Stockholm for Advanced RWE Analysis of Temodex
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio